Diabetes Mellitus Is a Strong Independent Negative Prognostic Factor in Patients with Brain Metastases Treated with Radiotherapy

Seong Hoon Jeong(Leipzig University), Clemens Seidel(Leipzig University), Kirsten Papsdorf(Leipzig University), Peter Hambsch(Leipzig University), Alexander Rühle(University of Freiburg), Sabine Klagges(University Hospital Leipzig), Johannes Wach(Leipzig University), Thomas Kuhnt(Leipzig University), Nils H. Nicolay(University Hospital Leipzig), Franziska Nägler(Leipzig University), Soniya Poudyal(Leipzig University), Erdem Güresir(University Hospital Leipzig)
Cancers
October 4, 2023
10.3390/cancers15194845
Cited by 2

Related Papers

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
|The Lancet|2019|581
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|550
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
|JAMA Oncology|2021|369
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
|International Journal of Radiation Oncology*Biology*Physics|2000|218
Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis
|International Journal of Radiation Oncology*Biology*Physics|2003|197